|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
and Endothelin-1 Increase P-Glycoprotein Expression and Transport Activity at the Blood-Brain BarrierLaboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina
The ATP-driven drug efflux pump, P-glycoprotein, is a critical and selective element of the blood-brain barrier and a primary impediment to pharmacotherapy of central nervous system (CNS) disorders. Thus, an understanding of how P-glycoprotein function is regulated has the potential to improve CNS therapy. We recently demonstrated rapid (minutes) and reversible inactivation of P-glycoprotein in rat brain capillaries signaled through tumor necrosis factor-
(TNF-
) and endothelin-1 (ET-1), components of the brain's innate immune response. In this study, we examined the longer-term consequences of continuous exposure of rat brain capillaries to low levels of TNF-
and ET-1. Exposing brain capillaries to TNF-
or ET-1 caused a rapid decrease in P-glycoprotein transport activity with no change in transporter protein expression. This was followed by a 2- to 3-h plateau at the low activity level and then by a sharp increase in both transport activity and protein expression. After 6 h, transport activity and transporter protein expression was double that of control samples. TNF-
signaled through TNF-R1, which in turn caused ET release and action through ETA and ETB receptors, nitric-oxide synthase, protein kinase C and nuclear factor-
B (NF-
B) and finally increased P-glycoprotein expression and transport activity. Assuming similar effects occur in vivo, the present results imply a tightening of the selective blood-brain barrier with chronic inflammation and thus reduced efficacy of CNS-acting drugs that are P-glycoprotein substrates. Moreover, involvement of NF-
B raises the possibility that other effectors acting through this transcription factor may have similar effects on this key blood-brain barrier transporter.
Received for publication August 1, 2006.
Accepted for publication November 28, 2006.
Address correspondence to: Dr. David S. Miller, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, 111 TW Alexander Dr, PO Box 12233, MD F203, Research Triangle Park, NC 27709. E-mail: miller{at}niehs.nih.gov
This article has been cited by other articles:
![]() |
W. Wang, S. Bansal, S. Falk, D. Ljubanovic, and R. Schrier Ghrelin protects mice against endotoxemia-induced acute kidney injury Am J Physiol Renal Physiol, October 1, 2009; 297(4): F1032 - F1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Xiong, D. Callaghan, A. Jones, J. Bai, I. Rasquinha, C. Smith, K. Pei, D. Walker, L.-F. Lue, D. Stanimirovic, et al. ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood-Brain Barrier for A{beta}1-40 Peptides J. Neurosci., April 29, 2009; 29(17): 5463 - 5475. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ott, G. Fricker, and B. Bauer Pregnane X Receptor (PXR) Regulates P-Glycoprotein at the Blood-Brain Barrier: Functional Similarities between Pig and Human PXR J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 141 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. S. Hartz, B. Bauer, M. L. Block, J.-S. Hong, and D. S. Miller Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P-glycoprotein up-regulation at the blood-brain barrier FASEB J, August 1, 2008; 22(8): 2723 - 2733. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Miller, B. Bauer, and A. M. S. Hartz Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy Pharmacol. Rev., June 1, 2008; 60(2): 196 - 209. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bauer, A. M. S. Hartz, A. Pekcec, K. Toellner, D. S. Miller, and H. Potschka Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling Mol. Pharmacol., May 1, 2008; 73(5): 1444 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Banks, S. Dohgu, J. L. Lynch, M. A. Fleegal-DeMotta, M. A. Erickson, R. Nakaoke, and T. Q. Vo Nitric Oxide Isoenzymes Regulate Lipopolysaccharide-Enhanced Insulin Transport across the Blood-Brain Barrier Endocrinology, April 1, 2008; 149(4): 1514 - 1523. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Maeng, M.-H. Kim, H.-E. Jin, S. M. Shin, T. Tsuruo, S. G. Kim, D.-D. Kim, C.-K. Shim, and S.-J. Chung Functional Induction of P-glycoprotein in the Blood-Brain Barrier of Streptozotocin-Induced Diabetic Rats: Evidence for the Involvement of Nuclear Factor-{kappa}B, a Nitrosative Stress-Sensitive Transcription Factor, in the Regulation Drug Metab. Dispos., November 1, 2007; 35(11): 1996 - 2005. [Abstract] [Full Text] [PDF] |
||||